237 related articles for article (PubMed ID: 20157776)
21. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors and their side effects: what hand surgeons should know.
Loeffler BJ; Gaston RG
J Hand Surg Am; 2010 Jul; 35(7):1206-8. PubMed ID: 20185252
[No Abstract] [Full Text] [Related]
23. Translating trial data into patients benefits: making the right choice.
Chlebowski RT
Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
[TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitor-associated arthralgias.
Chlebowski RT
J Clin Oncol; 2009 Oct; 27(30):4932-4. PubMed ID: 19752332
[No Abstract] [Full Text] [Related]
25. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
27. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
Younus J; Vandenberg TA
Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
[TBL] [Abstract][Full Text] [Related]
28. Toxicity of aromatase inhibitors.
Pandya N; Morris GJ
Semin Oncol; 2006 Dec; 33(6):688-95. PubMed ID: 17145349
[TBL] [Abstract][Full Text] [Related]
29. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
31. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Monnier A
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
[TBL] [Abstract][Full Text] [Related]
32. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
Bauerschlag D; Schem C; Maass N; Jonat W
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
[TBL] [Abstract][Full Text] [Related]
33. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Nishiyama K; Inaji H
Anticancer Res; 2009 Nov; 29(11):4791-4. PubMed ID: 20032437
[TBL] [Abstract][Full Text] [Related]
34. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
Goss PE
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
[TBL] [Abstract][Full Text] [Related]
35. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
36. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
37. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
Bria E; Ciccarese M; Giannarelli D; Cuppone F; Nisticò C; Nuzzo C; Natoli G; Fabi A; Terzoli E; Cognetti F; Carlini P
Cancer Treat Rev; 2006 Aug; 32(5):325-32. PubMed ID: 16766125
[TBL] [Abstract][Full Text] [Related]
38. Aromatase inhibitors as adjuvant treatment of breast cancer.
Geisler J; Lønning PE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):53-61. PubMed ID: 16337805
[TBL] [Abstract][Full Text] [Related]
39. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
40. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer.
Scarpa R; Atteno M; Peluso R; Costa L; Padula S; Di Minno D; Caso F; Iervolino S; Vitiello M; Del Puente A
J Clin Rheumatol; 2011 Jun; 17(4):169-72. PubMed ID: 21617557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
